March 21, 2025

Pushing the limits of ‘custom-made’ microscopy

Pushing the limits of ‘custom-made’ microscopy

Another EMBL-engineered advance to Brillouin microscopy significantly widens the aperture and provides for quick, more efficient 3-D imaging of light-sensitive samples

An artist’s representation of the new Brillouin microscopy approach that allows entire light-sheets to interact with 3D biological samples. The scattered light reveals a unique optical interference signal that can be recorded with a custom-developed spectrometer, tremendously speeding up image acquisition. Credit: Daniela Velasco/EMBL

Summary

  • PreviouslyEMBL scientists developed a new microscope based on Brillouin scattering – a phenomenon where light interacts with naturally occurring thermal vibrations within materials, from which their mechanical properties can be deduced. This method has since been used for non-invasive and live-imaging applications in biology, and that advance was selected as one of The Guardian’s 10 biggest science stories of 2022.
  • In a new paper, the same scientists have now succeeded in substantially further advancing Brillouin microscopy, making it approximately a thousand times faster and more efficient.
  • Simultaneously, the new microscopy method expands the swath of material it can view – from a 100-pixel line to a ~10,000-pixel full plane, capturing 3D images quickly enough for live-organism observation.

A new paper updates an EMBL technology advance even further. More details about the original technology can be found in our initial reporting here.

EMBL tech developers have made an important leap forward with a novel methodology that adds an important microscopy capability to life scientists’ toolbox. The advance represents a 1,000-fold improvement in speed and throughput in Brillouin microscopy and provides a way to view light-sensitive organisms more efficiently.

“We were on a quest to speed up image acquisition,” said Carlo Bevilacqua, lead author on a paper published about this technological development in Nature Photonics and an optical engineer in EMBL’s Prevedel Team. “Over the years, we have progressed from being able to see just a pixel at a time to a line of 100 pixels, to now a full plane that offers a view of approximately 10,000 pixels.”

The technology is based on a phenomenon first predicted in 1922 by French physicist Léon Brillouin. He showed that when light is shone on a material, it interacts with naturally occurring thermal vibrations within, exchanging energy and thereby slightly shifting the frequency (or colour) of the light. Measuring the spectrum (colours) of the scattered light reveals information about a material’s physical characteristics.

Using Brillouin scattering for microscopy purposes came much later – in the early 2000s – when other technological advancements enabled scientists to measure tiny frequency shifts with high precision and sufficient throughput. This allowed them to compute mechanical properties of living biological samples. However, at that point, scientists were only able to view one pixel at a time. The process was therefore quite time-consuming, and it severely limited how the microscopy method could be used in biology. In 2022, Bevilacqua and others in the Prevedel group were able to first expand the field of view to a line, and now with this latest development, to a full 2D field of view, which also helps speed up 3D imaging.

“Just as the development of light-sheet microscopy here at EMBL marked a revolution in light microscopy because it allowed for faster, high-resolution, and minimally phototoxic imaging of biological samples, so too does this advance in the area of mechanical or Brillouin imaging,” said Robert Prevedel, Group Leader and senior author on the paper. “We hope this new technology – with minimal light intensity – opens one more ‘window’ for life scientists’ exploration.”


Source article(s)

Full-field Brillouin microscopy based on an imaging Fourier transform spectrometer. Bevilacqua C. and Prevedel R. Nature Photonics 20 February 2025 10.1038/s41566-025-01619-y

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp